Fig. 4: Proof of concept demonstrating efficacy of SpA*, LukAB CC8Δ10C and SpA* + LukAB ( + AS01B) in the minipig SSI model in the deep, mid and top muscle, skin and the spleen. | npj Vaccines

Fig. 4: Proof of concept demonstrating efficacy of SpA*, LukAB CC8Δ10C and SpA* + LukAB ( + AS01B) in the minipig SSI model in the deep, mid and top muscle, skin and the spleen.

From: A SpA+LukAB vaccine targeting Staphylococcus aureus evasion factors restricts infection in two minipig infection models

Fig. 4

Göttingen minipigs (n = 3/group) received three vaccinations with 50 µg SpA*, 50 µg SpA* + 100 µg LukAB CC8Δ10C or 100 µg LukAB CC8Δ10C all adjuvanted with AS01B (25 µg MPL and 25 µg QS 21) or adjuvant control at 21-day intervals. Three weeks post the third immunization, animals were challenged with 106 CFU S. aureus CC398 in the minipig SSI model as previously described8, and the bacterial burden was determined 8 days later. Each point represents a single animal. Open symbols indicate censored values that are at the limit of detection of the plate reader. The mean of each group is indicated. Statistical significance was determined using Tobit model with Bonferroni correction; *P < 0.05. AS01B Adjuvant System AS01B CC clonal complex, LukAB leukocidin AB, SpA Staphylococcal protein A.

Back to article page